Institutional Repository of Dalian Institute of Chemical Physics, CAS
Not a member yet
45557 research outputs found
Sort by
Visible-light-induced dearomative spirolactonization of non-phenolic biaryl carboxylic acids
No full textThree-Dimensional Ordered Macroporous Metal-Organic Framework Single Crystal-Derived Nitrogen-Doped Hierarchical Porous Carbon for High-Performance Potassium-Ion Batteries
No full textThe biggest challenge of potassium-ion batteries (KIBs) application is to develop high-performance electrode materials to accommodate the potassium ions large size. Herein, by rational design, we carbonize three-dimensional (3D) ordered macroporous ZIF-8 to fabricate 3D interconnected nitrogen-doped hierarchical porous carbon (N-HPC) that shows excellent rate performance (94 mAh g(-1) at 10.0 A g(-1)), unprecedented cycle stability (157 mA g(-1) after 12000 cycles at 2.0 A g(-1)), and superior reversible capacity (292 mAh g(-1) at 0.1 A g(-1)). The 3D hierarchical porous structure diminishes the diffusion distance for both ions/electrons, while N-doping improves the reactivity and electronic conductivity via producing more defects. In addition, the bicontinuous structure possesses a large specific surface area, decreasing the current density, again improving the rate performance. In situ Raman spectra analysis confirms the potassiation and depotassiation in the N-HPC are highly reversible processes. The galvanostatic intermittent titration measurement and first-principles calculations reveal that the interconnected macropores are more beneficial to the diffusion of the K+. This 3D interpenetrating structure demonstrates a superiority for energy storage applications
Multiscale modeling of carrier transport in photocatalytic materials: Application to bismuth vanadate BiVO4
No full text
Enhancing single-molecule magnet behaviour through decorating terminal ligands in Dy-2 compounds
No full textThe utilization of two isomorphic ligands with different substituents leads to two centrosymmetric Dy-III dimers, namely, [Dy-2(bfbpen)(2)(H2O)(2)]center dot 2I(-) (1) and [Dy-2(bcbpen)(2)(H2O)(2)]center dot 2I(-)center dot 0.5H(2)O (2) (H(2)bfbpen = N,N '-bis-(2-hydroxy-5-fluoro-benzyl)-N,N '-bis-(pyridin-2-ylmethyl)ethylenediamine and H(2)bcbpen = N,N '-bis-(2-hydroxy-5-chloro-benzyl)-N,N '-bis-(pyridin-2-ylmethyl)ethylenediamine). Although Dy ions in both compounds uniformly exhibit a square-antiprism geometry, the critical difference found in the terminal substituents of the two ligands fine-tunes the local crystal field around Dy centers and the dinuclear molecular structures of 1 and 2. Magnetic investigations unveil that both 1 and 2 display dynamic magnetic relaxation of single-molecule magnet (SMM) behaviour with different energy barriers of 20.9 K for 1 and 72.7 K for 2 under a zero direct-current (dc) field, as well as 26.9 K for 1 under a 1200 Oe dc field. Compared to 1, the stronger uniaxial anisotropy and magnetic exchange in 2 render it a better SMM as evidenced by the higher energy barrier. Ab initio calculations are also performed on both Dy-2 compounds to rationalize the observed discrepancy in their magnetic behaviours. The contribution illustrates that the SMM behaviour could be effectively enhanced by means of deliberate local structural manipulation
effectsofniaoduqingparticles尿毒清颗粒ondelayingprogressionofrenaldysfunctionaposttrialopenlabelfollowupstudy
No full textObjective:To follow up the participants of the randomized clinical trial "Efficacy and Safety of Niaoduqing Particles(尿毒清颗粒) for Delaying Moderate-to-Severe Renal Dysfunction", and assess the long-term effects of Niaoduqing Particles on delaying the progression of renal dysfunction. Methods: Participants, who had previously been randomly assigned to receive Niaoduqing Particles or placebo for 24 weeks(146 cases in each group), were invited to follow-up and all were administered Niaoduqing Particles 5 g thrice daily and 10 g before bedtime for 24 weeks. The primary endpoints were changes in baseline serum creatinine(Scr) and estimated glomerular filtration rate(e GFR) after completion of the open-label treatment period. Results: After the double-blind period, the median(interquartile range) changes in Scr were 1.1(–13.0–24.1) and 11.7(–2.6–42.9) μmol/L for the Niaoduqing Particle and placebo groups, respectively(P=0.008), and the median changes in e GFRs were –0.2(–4.3–2.7) and –2.21(–5.7–0.8) mL·min^-1·1.73 m^-2, respectively(P=0.016). There were significant differences in the double-blind period changes in renal function between groups. After the open-label period, the median changes in Scr were 9.0(–10.0–41.9) and 17.5(–6.0–50.0) μmol/L for the Niaoduqing Particle and placebo groups according to baseline grouping, respectively(P=0.214), and the median changes in eGFRs were –2.3(–6.4–1.9) and –3.7(–7.5–1.1) mL·min^-1·1.73 m^-2, respectively(P=0.134). There were no statistical differences in the open-label period changes in renal function between groups. The eGFR reduction of participants who accepted Niaoduqing Particle treatment for 48 weeks was projected to 2.5 m L·min^-1·1.73 m^-2 per year. Conclusions: Niaoduqing Particles appear to have long-term efficacy for patients with moderate-to-severe renal dysfunction. Although there was no statistical difference, the early use of Niaoduqing Paticles seems to ameliorate the worsening of renal function